|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
SCIDIR_ocn874321486 |
003 |
OCoLC |
005 |
20231120111544.0 |
006 |
m o d |
007 |
cr ||||||||||| |
008 |
140322t20142014enka ob 100 0 eng d |
040 |
|
|
|a EBLCP
|b eng
|e rda
|e pn
|c EBLCP
|d OCLCQ
|d OPELS
|d N$T
|d OCLCF
|d OCLCQ
|d DEBSZ
|d MMU
|d OCL
|d FEM
|d OCLCO
|d MERUC
|d OCLCO
|d OCLCQ
|d CASUM
|d OCLCO
|d OCLCA
|d U3W
|d OCLCO
|d D6H
|d OCLCO
|d OTZ
|d OCLCQ
|d OCLCO
|d OCLCA
|d DCT
|d OCLCQ
|d OCLCO
|d S2H
|d OCLCO
|d COM
|d OCLCO
|d OCLCQ
|d OCL
|d OCLCO
|
019 |
|
|
|a 968011337
|a 969015703
|
020 |
|
|
|a 9780128004616
|q (electronic bk.)
|
020 |
|
|
|a 0128004614
|q (electronic bk.)
|
020 |
|
|
|z 9780127999647
|
035 |
|
|
|a (OCoLC)874321486
|z (OCoLC)968011337
|z (OCoLC)969015703
|
050 |
|
4 |
|a QR188.3
|
060 |
|
4 |
|a 2014 F-677
|
060 |
|
4 |
|a WD 305
|
072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
082 |
0 |
4 |
|a 616.97/8
|
111 |
2 |
|
|a BCG and TNF Signaling in the Treatment and Prevention of Autoimmune Diseases
|n (1st :
|d 2013 :
|c London, England),
|j author.
|
245 |
1 |
4 |
|a The value of BCG and TNF in autoimmunity /
|c [edited by] Denise L. Faustman.
|
264 |
|
1 |
|a London :
|b Elsevier/Academic Press,
|c [2014]
|
264 |
|
4 |
|c �2014
|
300 |
|
|
|a 1 online resource (xv, 164 pages) :
|b illustrations (chiefly color)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
336 |
|
|
|a still image
|b sti
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
504 |
|
|
|a Includes bibliographical references.
|
505 |
0 |
|
|a Mycobacteria, immunoregulation, and autoimmunity -- Prevention of Type 1 Diabetes and its recurrence by immunotherapy with mycobacterial adjuvants -- Proteasome defects and cytokine signaling on Sjogren's syndrome -- The protective effect of the BCG vaccine on the development of Type 1 Diabetes in humans -- Effects of the bacillus Calmette-Gu�erin (BCG) vaccines in the demyelinating disease of the central nervous system -- TNF, BCG, and the proteasome in autoimmunity: an overview of the pathways & results of a phase I study in Type 1 diabetes -- Why test BCG in Sj�ogrens syndrome? -- Celiac disease as a model disorder for testing autoimmune therapeutics -- Delivering solutions and clinical benefits for diseases with small intermediate-size patient populations.
|
520 |
|
|
|a "The Value of BCG and TNF in Autoimmunity provides an overview of current research and thinking related to tumor necrosis factor (TNF) induction and the use of the bacillus Calmette-Gu�erin (BCG) vaccine as potential treatment approaches to diverse forms of autoimmunity. BCG, commonly known as an anti-tuberculosis vaccine, is being explored in worldwide clinical trials as an approach to the treatment of certain forms of autoimmunity. The scope of research behind this therapeutic approach spans from the basic science of TNF signaling to research in diverse autoimmune disciplines, such as type 1 diabetes and multiple sclerosis. Overall, the book focuses on the lessons that can be learned from the researchers' individual experiences and data, and provides a rationale for bringing the inexpensive, generic BCG vaccine to the forefront of clinical trials in different forms of autoimmunity"--Publisher's description.
|
588 |
0 |
|
|a Online resource; title from resource home page (ebrary, viewed March 7, 2016).
|
650 |
|
0 |
|a Autoimmune diseases
|x Immunotherapy.
|
650 |
|
0 |
|a BCG vaccines
|x Therapeutic use.
|
650 |
|
0 |
|a Tumor necrosis factor.
|
650 |
|
0 |
|a Autoimmunity.
|
650 |
1 |
2 |
|a Autoimmune Diseases
|x therapy
|0 (DNLM)D001327Q000628
|
650 |
1 |
2 |
|a BCG Vaccine
|x therapeutic use
|0 (DNLM)D001500Q000627
|
650 |
2 |
2 |
|a Autoimmunity
|0 (DNLM)D015551
|
650 |
2 |
2 |
|a Immunotherapy
|x methods
|0 (DNLM)D007167Q000379
|
650 |
2 |
2 |
|a Tumor Necrosis Factors
|0 (DNLM)D048069
|
650 |
|
6 |
|a Maladies auto-immunes
|0 (CaQQLa)201-0064242
|x Immunoth�erapie.
|0 (CaQQLa)201-0380098
|
650 |
|
6 |
|a Auto-immunit�e.
|0 (CaQQLa)201-0060759
|
650 |
|
6 |
|a Facteurs de n�ecrose tumorale.
|0 (CaQQLa)201-0203643
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
650 |
|
7 |
|a Autoimmunity
|2 fast
|0 (OCoLC)fst00822674
|
650 |
|
7 |
|a Autoimmune diseases
|x Immunotherapy
|2 fast
|0 (OCoLC)fst00822669
|
650 |
|
7 |
|a BCG vaccines
|x Therapeutic use
|2 fast
|0 (OCoLC)fst00824856
|
650 |
|
7 |
|a Tumor necrosis factor
|2 fast
|0 (OCoLC)fst01158755
|
655 |
|
2 |
|a Congress
|0 (DNLM)D016423
|
655 |
|
7 |
|a proceedings (reports)
|2 aat
|0 (CStmoGRI)aatgf300027316
|
655 |
|
7 |
|a Conference papers and proceedings
|2 fast
|0 (OCoLC)fst01423772
|
655 |
|
7 |
|a Conference papers and proceedings.
|2 lcgft
|
655 |
|
7 |
|a Actes de congr�es.
|2 rvmgf
|0 (CaQQLa)RVMGF-000001049
|
700 |
1 |
|
|a Faustman, Denise,
|e editor.
|
776 |
0 |
8 |
|i Print version:
|a BCG and TNF Signaling in Autoimmunity (Conference) (2013 : London, England).
|t Value of BCG and TNF in autoimmunity.
|d Amsterdam : Elsevier, Academic Press, [2014]
|z 9780127999647
|w (DLC) 2012276564
|w (OCoLC)885014725
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780127999647
|z Texto completo
|